Joint-health PEA ingredient debuting at SupplySide West
Gencor, Levagen’s supplier, says the ingredient has been clinically shown to benefit those suffering from joint discomfort, and that it also supports a healthy anti-inflammatory response.
Photo © Shutterstock.com/Sebastian Kaulitzki
A new, branded palmitoylethanolamide (PEA) ingredient for joint health called Levagen will make its debut at November’s SupplySide West trade show. Gencor (Irvine, CA), Levagen’s supplier, says the ingredient has been clinically shown to benefit those suffering from joint discomfort, and that it also supports a healthy anti-inflammatory response.
“PEA was first identified in the 1950s as a therapeutic substance with potential anti-inflammatory properties,” the company explains in a press release. “It is produced in the body as a biological response and as a repair mechanism for inflammation. Levagen utilizes the endocannabinoid system for supporting joint function, reducing joint stiffness, and providing joint comfort.”
At SupplySide West, Gencor will also introduce a cold-water-dispersible version of Levagen, called Levagen+, that enhances bioavailability in aqueous environments, including the stomach, thanks to the use of LipiSperse dispersibility technology from an Australian company called Pharmako Biotechnologies, which is a partner of Gencor. The company claims Levagen+ supplies the largest amount of PEA, at over 90% loading, in a water-dispersible formulation.
Gencor says Levagen is supported by research and self-affirmed GRAS status. “PEA is the first of the next-generation anti-inflammatory analgesics,” said Chase Shryoc, vice president of business development, Gencor, in a press release.
Visit Gencor at SupplySide West Booth #4773
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.
Survey finds a lack of enthusiasm about AI technology among food and beverage consumers
December 12th 2024The survey, commissioned by Ingredient Communications and conducted by SurveyGoo, found that 83% of respondent agreed that companies should declare on product labels when a product has been designed or manufactured with the assistance of AI technology.
Kelker Pharma to launch nutritional support system for GLP-1 medication users that features TriBsyn
December 11th 2024B&D Nutritional Ingredients Inc., an exclusive distribution partner of CarnoSyn Brands and Natural Alternatives International Inc., announced that its customer, Kelker Pharma, will be launching the “first science-backed nutritional support system” for GLP-1 medication users, called Nutrilinq Genesis.
